Mycobacterium marinum infection complicated by anti-tumour necrosis factor therapy

References

1. Boulman N., Rozenbaum M., Slobodin G., Rosner I. 2006; Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis. Clin Exp Rheumatol 24:723
   [Google Scholar]
2. Chopra N., Kirschenbaum A. E., Widman D. 2002; Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis. J Clin Rheumatol 8:265–268 [CrossRef]
   [Google Scholar]
3. Danko J. R., Gilliland W. R., Miller R. S., Decker C. F. 2009; Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy. Scand J Infect Dis 41:252–255 [CrossRef]
   [Google Scholar]
4. Dare J. A., Jahan S., Hiatt K., Torralba K. D. 2009; Reintroduction of etanercept during treatment of cutaneous Mycobacterium marinum infection in a patient with ankylosing spondylitis. Arthritis Rheum 61:583–586 [CrossRef]
   [Google Scholar]
5. Díaz F., Urkijo J. C., Mendoza F., de la Viuda J. M., Blanco M., Unzurrunzaga A., Ayarza R. 2008; Mycobacterium chelonae infection associated with adalimumab therapy. Scand J Rheumatol 37:159–160 [CrossRef]
   [Google Scholar]
6. Ehlers S. 2005; Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?. Clin Infect Dis 41:S199–S203 [CrossRef]
   [Google Scholar]
7. Fallon J. C., Patchett S., Gulmann C., Murphy G. M. 2008; Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab. Clin Exp Dermatol 33:43–45
   [Google Scholar]
8. Griffith D. E., Aksamit T., Brown-Elliott B. A., Catanzaro A., Daley C., Gordin F., Holland S. M., Horsburgh R., Huitt G. other authors 2007; An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367–416 [CrossRef]
   [Google Scholar]
9. Keane J., Gershon S., Wise R. P., Mirabile-Levens E., Kasznica J., Schwieterman W. D., Siegel J. N., Braun M. M. 2001; Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104 [CrossRef]
   [Google Scholar]
10. Malkin J., Shrimpton A., Wiselka M., Barer M. R., Duddridge M., Perera N. 2009; Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet's disease. J Med Microbiol 58:371–373 [CrossRef]
    [Google Scholar]
11. Marie I., Heliot P., Roussel F., Hervé F., Muir J. F., Levesque H. 2005; Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology 44:1201–1202 [CrossRef]
    [Google Scholar]
12. Martín-Aspas A., Guerrero-Sánchez F., García-Martos P., González-Moya E., Medina-Varo F., Girón González J. A. 2008; Bilateral pneumonia by Mycobacterium aurum in a patient receiving infliximab therapy. J Infect 57:167–169 [CrossRef]
    [Google Scholar]
13. Mufti A. H., Toye B. W., Mckendry R. R., Angel J. B. 2005; Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. Diagn Microbiol Infect Dis 53:233–238 [CrossRef]
    [Google Scholar]
14. Pandian T. K., Deziel P. J., Otley C. C., Eid A. J., Razonable R. R. 2008; Mycobacterium marinum infections in transplant recipients: case report and review of the literature. Transpl Infect Dis 10:358–363 [CrossRef]
    [Google Scholar]
15. Piersimoni C., Scarparo C. 2009; Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis 15:1351–1358 [CrossRef]
    [Google Scholar]
16. Rallis E., Koumantaki-Mathioudaki E., Frangoulis E., Chatziolou E., Katsambas A. 2007; Severe sporotrichoid fish tank granuloma following infliximab therapy. Am J Clin Dermatol 8:385–388 [CrossRef]
    [Google Scholar]
17. Salvana E. M., Cooper G. S., Salata R. A. 2007; Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J Infect 55:484–487 [CrossRef]
    [Google Scholar]
18. Shehan J. M., Sarma D. P. 2008; Mycobacterium mucogenicum : report of a skin infection associated with etanercept. Dermatol Online J 14:5
    [Google Scholar]
19. Streit M., Böhlen L. M., Hunziker T., Zimmerli S., Tscharner G. G., Nievergelt H., Bodmer T., Braathen L. R. 2006; Disseminated Mycobacterium marinum infection with extensive cutaneous eruption and bacteremia in an immunocompromised patient. Eur J Dermatol 16:79–83
    [Google Scholar]
20. Swart R. M., van Ingen J., van Soolingen D., Slingerland R., Hendriks W. D., den Hollander J. G. 2009; Nontuberculous mycobacteria infection and tumor necrosis factor-alpha antagonists. Emerg Infect Dis 15:1700–1701 [CrossRef]
    [Google Scholar]
21. van Ingen J., Boeree M., Janssen M., Ullmann E., de Lange W., de Haas P., Dekhuijzen R., van Soolingen D. 2007; Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol 3:414–419
    [Google Scholar]
22. Wallis R. S., Broder M. S., Wong J., Beenhouwer D. 2004; Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39:1254–1255 [CrossRef]
    [Google Scholar]
23. Winthrop K. L., Chang E., Yamashita S., Iademarco M. F., LoBue P. A. 2009; Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 15:1556–1561 [CrossRef]
    [Google Scholar]
24. Yim K., Nazeer S. H., Kiska D., Rose F. B., Brown D., Cynamon M. H. 2004; Recurrent Mycobacterium xenopi infection in a patient with rheumatoid artritis receiving etanercept. Scand J Infect Dis 36:150–154 [CrossRef]
    [Google Scholar]